REQUEST FOR PROPOSALS

Takeda California, Inc. (TCAL) is the Center for Excellence in Structure Based Drug Discovery and Antibody Research for Takeda Pharmaceutical Company Limited. TCAL’s therapeutic areas of interest are oncology, metabolic disease, inflammation and CNS. Particular current areas of interest are appended to the end of this request.

TCAL invites academic researchers and their institutions to contact TCAL with non-confidential drug discovery-related proposals for potential research collaborations with TCAL. Proposals will be evaluated based on (i) the time and effort required to progress the collaboration to the clinical evaluation of a novel therapeutic agent; (ii) the associated project risks; and (iii) the potential commercial opportunity. For proposals that are found to be of interest, TCAL will enter into confidentiality agreements and entertain more detailed confidential proposals and discussions regard a potential collaboration.

Ideally, research collaborations will be based on intellectual property (patented, patent pending or know-how) already developed by the researcher that TCAL can leverage in conjunction with its internal research efforts to identify and progress a drug candidate to clinical trials. The intellectual property ideally facilitates the identification of novel therapeutic agents, advantageous indications and/or patient populations to target.

Examples of intellectual property to be contributed to the collaboration by the academic researcher include:

- Evidence of validation for particular targets or pathways (e.g., effects of pharmacological inhibition)
- Biomarkers or disease models that allow for better evaluation of potential therapeutic agents
- Biomarkers that can be used to select preferred patient populations
- Novel chemical series directed to particular therapeutic targets
- Novel antibodies or antibody drug conjugates
- Conjugation reagents and chemistry for the formation of antibody drug conjugates

Projects related to the following area of research will typically be outside of the scope of interest of TCAL at this time:

- Efforts to identify new targets or generate validation of targets
- High-throughput screening projects
- Vaccines
- Stem cell research
- Gene therapy
- Therapeutics other than small molecule and antibody or antibody conjugates

A successful collaboration will involve TCAL working internally to identify and progress drug candidates to clinical trials. The collaboration may also involve time limited funding of the submitting researcher’s lab to fund research that is coordinated with TCAL’s efforts and focused on supporting TCAL’s internal drug discovery efforts. The level of funding will be evaluated on a case by case basis and is anticipated to typically be in the $250,000 - $1,000,000 range over a 12-18 month timeframe. The academic research group is encouraged to propose the scope and nature of the further work they would do to help progress the collaboration to clinical evaluation, their unique ability to do that work, and the associated funding requirements.

Appended is a worksheet to assist researchers to most efficiently summarize their research proposals for TCAL’s consideration.

PROPOSAL SUBMISSION / CONTACT INFORMATION

Prospective collaborators and their technology licensing office representatives are encouraged to submit inquiries and proposals to Takeda California Business Development at BusDev@takedasd.com.
# ACADEMIC RESEARCH COLLABORATION PROPOSAL WORKSHEET

(Please submit worksheet to Takeda California Business Development at [BusDev@takedasd.com](mailto:BusDev@takedasd.com))

## Principal Applicant

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Address and contact details</th>
<th>Email address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Technology Transfer Officer

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Address and contact details</th>
<th>Email address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Title for proposal

Title

---

### Summary of why Takeda should enter into a collaboration based on intellectual property being contributed (1/2 page)

e.g., (a) disease indication and prevalence; (b) medical need and the potential impact on healthcare (e.g. suboptimal existing treatments, unmet medical need, etc); (c) commercial potential of resulting products; (d) description and validation of target; (e) competitive advantage of proposed approach (e.g. greater efficacy, improved safety, preferable point of interaction etc); (f) competitive advantage offered by researcher's intellectual property; and (g) availability of chemistry starting points

---

### 5 most relevant references as background to proposal

References

---

### Estimated timeline to drug candidate selection and clinical evaluation (1/2 page)

Timeline

---

### Proposed scope of further work, timeline, and deliverables of funded research to be performed by researcher under collaboration (1/2 page)

Scope

---

### Outline of the project costs for researcher's portion of research effort (e.g. Total salaries requested; outsourced services, etc, inclusive of institutional overhead) (1/2 page)

Costs
General status of intellectual property available to contribute to collaboration

Known freedom to operate issues